Granules India Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Thu Jan 22 2026

Granules India Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Granules India’ Q3 results FY26 are scheduled to be announced on 23rd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Granules India Q3 Results 2026 Preview

Granules India’s revenue is expected to be in the range of ₹,137.70 crore, a 17.70% YoY increase.
Profit After Tax, or PAT, is projected to rise by 20.95% YoY.
Granules India’s EBITDA is expected to rise to ₹173.68 crore.
Net profit is ₹117.60 crore, up 20.95% YoY

Granules India Share Performance

Over the past six months, Granules India’s share price has fallen by 15.18% to ₹5.53.
Moreover, over the past year, the stock has decreased by 23.83%.
Despite this weak short-term performance, Granules India’s stock has delivered a financially sound 1.25% return over the past 5 years.
As of 22nd January 2026, the stock traded at ₹69.60 per share.

Key Factors to Watch for Granules India Q3 Results FY26

Revenue & Segment Mix: Performance across APIs, PFIs and finished dosages, with focus on formulation-led growth.
Margins & Profitability: EBITDA and PAT margin trends driven by product mix, pricing and cost efficiencies.
Regulatory Updates: USFDA compliance status and any impact on exports and production continuity.
Capacity Expansion & Pipeline: Progress on new facilities, ANDA approvals, and product launch outlook.

Final Thoughts

Granules India will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 17.70% YoY revenue growth, a 20.95% rise in PAT, and an 15.18% rise in EBITDA. Granules India focuses on growing its integrated pharmaceutical business by expanding APIs, PFIs and finished dosage formulations, strengthening global (especially U.S.) exports, enhancing regulatory compliance and approvals, and scaling capacity through new plants and product launches.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!